8-K current report · filed Jul 22, 2026

BIOLIFE SOLUTIONS INC (BLFS) 8-K Current Report: July 22, 2026

Item 1.01Item 2.02Item EX-99.1Item 7.01BLFS overview

Short answer

BIOLIFE SOLUTIONS INC (BLFS) filed an 8-K current report with the SEC on July 22, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Repligen acquisition consideration: $11.25 cash plus 0.1442 Repligen shares per BioLife share.

BIOLIFE SOLUTIONS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Repligen acquisition consideration: $11.25 cash plus 0.1442 Repligen shares per BioLife share
  • Transaction structure: BioLife becomes a wholly owned Repligen subsidiary through two sequential mergers
  • Expected closing: fourth quarter 2026, subject to BioLife stockholder approval, antitrust clearance and SEC effectiveness of Form S-4
  • Equity awards accelerate at closing, including options, time-based RSUs, performance-based PSUs and restricted stock awards
  • BioLife termination fee: $59 million under specified competing-bid or recommendation-change scenarios

Item 2.02 · Results of Operations and Financial Condition

  • BioLife announced preliminary unaudited revenue for Q2 ended June 30, 2026
  • Revenue figures and operating commentary are contained in Exhibit 99.1
  • Preliminary status means results remain subject to finalization and potential adjustment

Item 7.01 · Regulation FD Disclosure

  • BioLife and Repligen announced a merger agreement on July 22, 2026
  • Employee town hall presentation accompanied the merger announcement
  • Transaction terms and strategic implications are in Exhibit 99.1; employee communications are in Exhibit 99.2

Item EX-99.1 · Exhibit EX-99.1

  • Repligen to acquire BioLife for approximately $1.5B enterprise value, offering $31.00 per share and a 24% premium to 90-day VWAP
  • Consideration mix: 64% Repligen stock and 36% cash, including $11.25 cash plus 0.1442 Repligen shares per BioLife share
  • BioLife shareholders gain immediate cash and continued upside exposure, while accepting transaction-completion and stock-value risks
  • BioLife preliminary Q2 revenue $28.5M, up 21% from $23.4M; standalone earnings call canceled pending acquisition
  • Closing targeted for Q4 2026, subject to regulatory clearance, BioLife shareholder approval, and customary conditions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other BIOLIFE SOLUTIONS INC 8-K filings

Get the next BLFS 8-K as it lands

Follow BLFS for push alerts, or ask the research agent what this filing means.